Literature DB >> 17706160

Pentostatin, cyclophosphamide, and rituximab show significant clinical activity in patients with previously untreated chronic lymphocytic leukemia.

Nicole Lamanna, Mark A Weiss.   

Abstract

Entities:  

Year:  2007        PMID： 17706160     DOI： 10.1007/s11912-007-0044-x

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  9 in total

Review 1.  Advances in the treatment of chronic lymphocytic leukemia.

Authors:  Nicole Lamanna
Journal:  Curr Oncol Rep       Date:  2005-09       Impact factor: 5.075

Review 2.  B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL.

Authors:  G Dighiero; P Travade; S Chevret; P Fenaux; C Chastang; J L Binet
Journal:  Blood       Date:  1991-10-15       Impact factor: 22.113

3.  Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia.

Authors:  M R Grever; K J Kopecky; C A Coltman; J C Files; B R Greenberg; J J Hutton; R Talley; D D Von Hoff; S P Balcerzak
Journal:  Nouv Rev Fr Hematol       Date:  1988

4.  Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Authors:  Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William Wierda; Michelle A Detry; Alice Lynn; Hagop Kantarjian
Journal:  J Clin Oncol       Date:  2005-03-14       Impact factor: 44.544

5.  Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia.

Authors:  Mark A Weiss; Peter G Maslak; Joseph G Jurcic; David A Scheinberg; Timothy B Aliff; Nicole Lamanna; Stanley R Frankel; Steven E Kossman; Denise Horgan
Journal:  J Clin Oncol       Date:  2003-04-01       Impact factor: 44.544

6.  High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count.

Authors:  G Juliusson; J Liliemark
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

Review 7.  Advances in the biology and treatment of B-cell chronic lymphocytic leukemia.

Authors:  S O'Brien; A del Giglio; M Keating
Journal:  Blood       Date:  1995-01-15       Impact factor: 22.113

8.  Low-dose deoxycoformycin in lymphoid malignancy.

Authors:  M R Grever; J M Leiby; E H Kraut; H E Wilson; J A Neidhart; R L Wall; S P Balcerzak
Journal:  J Clin Oncol       Date:  1985-09       Impact factor: 44.544

9.  Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.

Authors:  Nicole Lamanna; Matt Kalaycio; Peter Maslak; Joseph G Jurcic; Mark Heaney; Renier Brentjens; Andrew D Zelenetz; Denise Horgan; Alison Gencarelli; Katherine S Panageas; David A Scheinberg; Mark A Weiss
Journal:  J Clin Oncol       Date:  2006-03-06       Impact factor: 50.717
  9 in total
  1 in total

Review 1.  Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly.

Authors:  Valentin Goede; Michael Hallek
Journal:  Drugs Aging       Date:  2011-03-01       Impact factor: 3.923
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.